The efficacy and economic evaluation of roxadustat treatment for anemia in patients with kidney disease not receiving dialysis

References

• Webster AC, Nagler EV, Morton RL, et al. Chronic kidney disease. Lancet. 2017;389(10075):1238–1252.
   PubMed Web of Science ®Google Scholar
• Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet. 2012;379(9818):815–822.
   PubMed Web of Science ®Google Scholar
• Collins AJ, Ma JZ, Xia A, et al. Trends in anemia treatment with erythropoietin usage and patient outcomes. Am J Kidney Dis. 1998;32(Suppl 6):S133–41.
   PubMedGoogle Scholar
• Park H, Liu X, Henry L, et al. Trends in anemia care in non-dialysis-dependent chronic kidney disease (CKD) patients in the United States (2006-2015). BMC Nephrol. 2018;19(1):318.
   PubMedGoogle Scholar
• Tarlov E, Stroupe KT, Lee TA, et al. Trends in anemia management in lung and colon cancer patients in the US Department of Veterans Affairs, 2002-2008. Support Care Cancer. 2012;20(8):1649–1657.
   PubMed Web of Science ®Google Scholar
• Padhi S, Glen J, Pordes BAJ, et al. Management of anaemia in chronic kidney disease: summary of updated NICE guidance. BMJ. 2015;350:h2258.
   PubMedGoogle Scholar
• Kliger AS, Foley RN, Goldfarb DS, et al. KDOQI US commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD. Am J Kidney Dis. 2013;62(5):849–859.
   PubMed Web of Science ®Google Scholar
• Group KAW. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int. 2012;4(Suppl 2):S279–335.
   Web of Science ®Google Scholar
• Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085–2098.
   PubMed Web of Science ®Google Scholar
• Finkelstein FO, Finkelstein SH. The impact of anemia treatment on health-related quality of life in patients with chronic kidney disease in the contemporary era. Adv Chronic Kidney Dis. 2019;26(4):250–252.
   PubMed Web of Science ®Google Scholar
• Leaf DE, Goldfarb DS. Interpretation and review of health-related quality of life data in CKD patients receiving treatment for anemia. Kidney Int. 2009;75(1):15–24.
   PubMed Web of Science ®Google Scholar
• Finkelstein FO, Story K, Firanek C, et al., Health-related quality of life and hemoglobin levels in chronic kidney disease patients. Clin J Am Soc Nephrol. 2009;4(1): 33–38.
   PubMed Web of Science ®Google Scholar
• Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355(20):2071–2084.
   PubMed Web of Science ®Google Scholar
• Palmer SC, Navaneethan SD, Craig JC, et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med. 2010;153(1):23–33.
   PubMed Web of Science ®Google Scholar
• Chen N, Hao C, Peng X, et al., Roxadustat for anemia in patients with kidney disease not receiving dialysis. N Engl J Med. 2019;381(11): 1001–1010.
   PubMed Web of Science ®Google Scholar
• Besarab A, Provenzano R, Hertel J, et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrol Dial Transplant. 2015;30(10):1665–1673.
   PubMed Web of Science ®Google Scholar
• Zhong H, Zhou T, Li H, et al. The role of hypoxia-inducible factor stabilizers in the treatment of anemia in patients with chronic kidney disease. Drug Des Devel Ther. 2018;12:3003–3011.
   PubMed Web of Science ®Google Scholar
• Akizawa T, Iwasaki M, Otsuka T, et al. Roxadustat treatment of chronic kidney disease-associated anemia in japanese patients not on dialysis: a phase 2, randomized, double-blind, placebo-controlled trial. Adv Ther. 2019;36(6):1438–1454.
   PubMed Web of Science ®Google Scholar
• Chen N, Qian J, Chen J, et al., Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrol Dial Transplant. 2017;32(8): 1373–1386.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
   PubMed Web of Science ®Google Scholar
• Aspinall SL, Smith KJ, Good CB, et al. Incremental cost effectiveness of pharmacist-managed erythropoiesis-stimulating agent clinics for non-dialysis-dependent chronic kidney disease patients. Appl Health Econ Health Policy. 2013;11(6):653–660.
   PubMedGoogle Scholar
• Organization WH. Cost effectiveness thresholds. Geneva: World Health Organization; 2011.
   Google Scholar
• YueHeng R. Therapeutic effect of stable hypoxia-inducible factor on anemia of chronic kidney disease and its mechanism of regulating related target genes. [doctoral dissertation]. Shanghai: Fudan University; 2013.
   Google Scholar
• Toft G, Heide-Jørgensen U, van Haalen H, et al. Anemia and clinical outcomes in patients with non-dialysis dependent or dialysis dependent severe chronic kidney disease: a Danish population-based study. J Nephrol. 2019;33:147–156.
   PubMed Web of Science ®Google Scholar
• Lawler EV, Bradbury BD, Fonda JR, et al., Transfusion burden among patients with chronic kidney disease and anemia. Clin J Am Soc Nephrol. 2010;5(4): 667–672.
   PubMed Web of Science ®Google Scholar
• Ara R, Brazier J. Deriving an algorithm to convert the eight mean SF-36 dimension scores into a mean EQ-5D preference-based score from published studies (where patient level data are not available). Value Health. 2008;11(7):1131–1143.
   PubMed Web of Science ®Google Scholar
• Kubasch AS, Platzbecker U. Setting fire to ESA and EMA resistance: new targeted treatment options in lower risk myelodysplastic syndromes. Int J Mol Sci. 2019;20(16):3853.
   PubMed Web of Science ®Google Scholar
• Chen N, Hao C, Liu B-C, et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis. N Engl J Med. 2019;381(11):1011–1022.
   PubMed Web of Science ®Google Scholar